Akebia Therapeutics, Inc. AKBA
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Akebia Therapeutics, Inc. (AKBA) is a healthcare company listed in the US with a market value of about $132M. In the twelve months to September 30, 2026 it had revenue of $197M and net income of -$45M, a net margin of -22.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is track record (0/5).
Key numbers: a price to free cash flow of 9.5, 5-year revenue growth of -4% a year, a 5-year average ROIC of -111%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 81% below the current price.
About Akebia Therapeutics
Akebia Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $181M in 2017 to $236M in 2025, growth of about 3.4% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 41% over three years (dilution for shareholders). It spends 26% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- P/FCF below 20
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $197M | $236M | $160M | $195M | $292M | $212M | $295M | $335M | $208M | $181M |
| Net income | -$45M | -$5M | -$69M | -$52M | -$94M | -$282M | -$385M | -$280M | -$144M | -$74M |
| Free cash flow | $14M | $68M | -$41M | -$23M | -$73M | -$253M | -$111M | -$264M | -$99M | -$58M |
| EPS (diluted) | $-0.16 | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 | $-2.78 | $-2.36 | $-2.47 | $-1.69 |
| Net margin | -22.6% | -2.3% | -43.3% | -26.7% | -32.2% | -133.2% | -130.6% | -83.5% | -69.1% | -40.6% |
| ROIC | — | 22.0% | — | -263.8% | -76.9% | -125.7% | -101.9% | -55.8% | -22.9% | -49.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Akebia Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 81% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Akebia Therapeutics pay a dividend?
Not currently.
Is Akebia Therapeutics a good stock to buy?
We do not give buy or sell advice. Akebia Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.